Hims rises on revenue beat, discloses it’s again in partnership talks with Novo

Hims & Hers reported third-quarter earnings results that missed Wall Street estimates but revenue that blew expectations out of the water. The company also said it’s talking with Novo Nordisk again about a potential deal to distribute its branded weight-loss drugs.

The company reported diluted earnings per share of $0.06, less than the $0.09 analysts polled by FactSet were expecting. Hims also reported $598.9 million in sales, significantly more than the $580.2 million the Street was penciling in.

The company narrowed its full-year revenue guidance to about $2.35 billion from between $2.3 billion and $2.4 billion.

Hims also disclosed on Monday that it’s in talks with Novo to make its branded weight-loss drugs available on the telehealth company’s platform. The two previously had a partnership that ended abruptly in June after Novo accused Hims of “illegal mass compounding and deceptive marketing.”

Hims has been looking for ways to spark sales growth as its core sexual health business slows down and its ability to sell weight-loss treatments remains on shaky ground. In recent months, the company has introduced testosterone treatments and menopause regimens, as well as GLP-1 “micro-dosing” options.

Additionally, the company disclosed that it’s continuing to explore international expansion “in key markets including Brazil, the U.K., Germany, and Australia.” Earlier this year, the company acquired a European peer, Zava, for $265.7 million, and announced plans to expand to Canada in 2026 to offer generic versions of Novo’s weight-loss shot.

Hims said it plans to launch “comprehensive lab testing capabilities in the near future.” That will support its upcoming “longevity” specialty as well as its injectable testosterone offerings, both of which it says are coming next year.